LeGrand Susan B, Leskuski Dona, Zama Ivan
Harry R. Horvitz Center for Palliative Medicine, Solid Tumor Oncology, Cleveland Clinic, Taussig Cancer Institute, 9500 Euclid Avenue R35, Cleveland, OH 44195, USA.
Ann Intern Med. 2008 Aug 19;149(4):259-63. doi: 10.7326/0003-4819-149-4-200808190-00007.
Although primary hyperparathyroidism is the most common cause of hypercalcemia, cancer is the most common cause requiring inpatient intervention. An estimated 10% to 20% of all patients with cancer have hypercalcemia at some point in their disease trajectory, particularly in advanced disease. Aggressive saline hydration and varying doses of furosemide continue to be the standard of care for emergency management. However, a review of the evidence for the use of furosemide in the medical management of hypercalcemia yields only case reports published before the introduction of bisphosphonates, in contrast to multiple randomized, controlled trials supporting the use of bisphosphonates. The use of furosemide in the management of hypercalcemia should no longer be recommended.
尽管原发性甲状旁腺功能亢进是高钙血症最常见的病因,但癌症是需要住院干预的最常见病因。据估计,所有癌症患者中约有10%至20%在其疾病进程中的某个阶段会出现高钙血症,尤其是在晚期疾病中。积极的生理盐水水化和不同剂量的呋塞米仍然是紧急处理的标准治疗方法。然而,对呋塞米用于高钙血症医学管理的证据进行回顾后发现,与支持使用双膦酸盐的多项随机对照试验形成对比的是,仅有在双膦酸盐引入之前发表的病例报告。不应再推荐使用呋塞米来管理高钙血症。